You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: angiotensin-converting enzyme inhibitors reduce the progression of non-diabetic renal disease

https://doi.org/10.1136/ebm.7.1.13

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Ann Intern Med 135, 73. Jafar TH, Schmid CH, Landa M. , et al, for the ACE Inhibition in Progressive Renal Disease Study Group. . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.. Jul 17;. :. –87.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with non-diabetic renal disease, are antihypertensive regimens with angiotensin-converting enzyme (ACE) inhibitors effective for slowing the progression of disease?

    Data sources

    Studies were identified by searching Medline (May 1977 to September 1997), scanning abstracts in the proceedings of US and international conferences, scrutinising bibliographies from relevant articles, and contacting investigators for unpublished data.

    Study selection

    English-language randomised controlled trials were selected if they compared the effectiveness of antihypertensive regimens containing ACE inhibitors (enalapril, captopril, benazepril, cilazapril, and ramipril) with that of antihypertensive regimens not containing ACE inhibitors (control group) in patients with non-diabetic renal disease, and if they had ≥ 1 year of follow up.

    Data extraction

    Data were extracted on sample size, patient characteristics, key components of the intervention, and outcomes. Main outcomes included end-stage renal disease (ESRD), defined as the initiation of long …

    View Full Text

    Footnotes

    • Sources of funding: National Institute of Diabetes and Digestive and Kidney Diseases; Agency for Healthcare Research and Quality; Dialysis Clinic, Inc.; Paul Teschan Research Fund; New England Medical Center–St. Elizabeth's Hospital Medical Center Clinical Research Fellowship Program; Merck Research Laboratories.

    • For correspondence: Dr A S Levey, Division of Nephrology, New England Medical Center, 750 Washington Street, Box 391, Boston, MA 02111, USA. Fax +1 617 636 8329.